-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$20.0086.39% Upside
Y-mAbs Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Y-mAbs Therapeutics, Inc.?
Y-mAbs Therapeutics, Inc. has been rated by research analysts at BMO Capital, Truist Financial, H.C. Wainwright, Wedbush in the past 90 days.